Completed PHASE2/PHASE3 INTERVENTIONAL 4-arm NCT00419146

Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants

A Multicentre, Placebo-controlled Trial of Eicosapentaenoic Acid (EPA) and Antioxidant Supplementation in the Treatment of Schizophrenia and Related Disorders

Sponsor: AstraZeneca

Conditions Psychotic Disorders Schizoaffective Disorder Schizophrenia Schizophreniform Disorders

Interventions Ethyl-eicosapentaenoic acid (EPA) Etyl EPA (placebo) Vitamins E + C Vitamins E+C (placebo)

Updated 5 times since 2017 Last updated: Jan 3, 2011 Started: Sep 30, 2001 Primary completion: Apr 30, 2004 Completion: Apr 30, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Psychotic Disorders and Schizoaffective Disorder, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 5 data snapshots since 2001. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Sep 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
Diakonhjemmet Hospital
Johanne and Einar Eilertsen's research fund
Josef and Haldis Andresen's legacy
Laxdale Ltd
Norwegian University of Science and Technology
Scandinavian Society for Psychopharmacology
Shipowner Emil Stray's legacy
Solveig and Johan P. Sommer's foundation
Stanley Medical Research Institute
University Hospital, Aker
University of Oslo

Data source: Oslo University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Oslo, Norway